Sequential delivery of photosensitizers and checkpoint inhibitors by engineered bacteria for enhanced cancer photodynamic immunotherapy
Biotechnology and Bioengineering · 2024
DOI: 10.1002/bit.28829 ↗At a glance
Journal article in Biotechnology and Bioengineering, 2024. Written by Xinyu Liu and 14 co-authors. Institution: School of Life Sciences, Tianjin University, Tianjin, China. Major MEDLINE topics: Photochemotherapy, Photosensitizing Agents, Escherichia coli, Immunotherapy. Cited 12 times so far (Crossref); 26 references. Funded by: National Key Research and Development Program of China, National Natural Science Foundation of China for Excellent Young Scholars, Tianjin Natural Science Foundation for Distinguished Young Scholars.
Abstract (original language)
Engineered bacteria‐based cancer therapy has increasingly been considered to be a promising therapeutic strategy due to the development of synthetic biology. Wherein, engineering bacteria‐mediated photodynamic therapy (PDT)‐immunotherapy shows greater advantages and potential in treatment efficiency than monotherapy. However, the unsustainable regeneration of photosensitizers (PSs) and weak immune responses limit the therapeutic efficiency. Herein, we developed an engineered bacteria‐based delivery system for sequential delivery of PSs and checkpoint inhibitors in cancer PDT‐immunotherapy. The biosynthetic pathway of 5‐aminolevulinic acid (5‐ALA) was introduced into Escherichia coli , yielding a supernatant concentration of 172.19 mg/L after 10 h of growth. And another strain was endowed with the light‐controllable releasement of anti‐programmed cell death‐ligand 1 nanobodies (anti‐PD‐L1). This system exhibited a collaborative effect, where PDT initiated tumor cell death and the released tumor cell fragments stimulated immunity, followed by the elimination of residual tumor cells. The tumor inhibition rate reached 74.97%, and the portion of activated T cells and inflammatory cytokines were reinforced. The results demonstrated that the engineered bacteria‐based collaborative system could sequentially deliver therapeutic substance and checkpoint inhibitors, and achieve good therapeutic therapy. This paper will provide a new perspective for the cancer PDT‐immunotherapy.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- School of Life Sciences, Tianjin University, Tianjin, China.
- Tianjin Engineering Center of Micro-Nano Biomaterials and Detection-Treatment Technology, Tianjin Key Laboratory of Function and Application of Biological Macromolecular Structures, Tianjin, China.
- School of Medical Imaging, Xuzhou Medical University, Xuzhou, China.
- Key Laboratory of Molecular Medicine and Biotherapy, School of Life Science, Beijing Institute of Technology, Beijing, China.
- Research Center of Clinical Epidemiology, Peking University Third Hospital, Beijing, China.
Funding
- National Key Research and Development Program of China
- National Natural Science Foundation of China for Excellent Young Scholars
- Tianjin Natural Science Foundation for Distinguished Young Scholars
- Key Program of Tianjin Natural Science Foundation
- Beijing-Tianjin-Hebei Basic Research Cooperation project, Beijing Natural Science Foundation of China
- National Natural Science Foundation of China
- Key Research and Development Program of Tianjin
- Youth Fund Project of Natural Science Foundation of Jiangsu Province
Cite
APA
Liu, X., Fan, Y., Zhang, X., Li, L., Yang, C., Ma, X., Bai, G., Sun, D., Wang, Y., Wang, J., Li, Y., Shi, Y., Liu, J., Zhang, Y., & Wang, H. (2024). Sequential delivery of photosensitizers and checkpoint inhibitors by engineered bacteria for enhanced cancer photodynamic immunotherapy. Biotechnology and Bioengineering. https://doi.org/10.1002/bit.28829
Vancouver
Liu X, Fan Y, Zhang X, Li L, Yang C, Ma X, et al. Sequential delivery of photosensitizers and checkpoint inhibitors by engineered bacteria for enhanced cancer photodynamic immunotherapy. Biotechnology and Bioengineering. 2024. doi:10.1002/bit.28829
BibTeX
@article{Liu2024,
author = {Liu, Xinyu and Fan, Yali and Zhang, Xinyu and Li, Lianyue and Yang, Chao and Ma, Xiaoyan and Bai, Guijie and Sun, Dawei and Wang, Yaxin and Wang, Junyi and Li, Yong and Shi, Yanyan and Liu, Jing and Zhang, Yingying and Wang, Hanjie},
title = {Sequential delivery of photosensitizers and checkpoint inhibitors by engineered bacteria for enhanced cancer photodynamic immunotherapy},
journal = {Biotechnology and Bioengineering},
year = {2024},
doi = {10.1002/bit.28829}
}
EUVIMED